Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies by Thompson, Peggy A, Eam, Boreth, Young, Nathan P, Fish, Sarah, Chen, Joan, Barrera, Maria, Howard, Haleigh, Parra, Ana, Molter, Jolene, Staunton, Jocelyn, Hung, Ivy NJ, Parker, Greg S, Chiang, Gary G, Wegerski, Chris J, Nevarez, Andres, Clarine, Jeff, Sperry, Sam, Xiang, Alan, Tran, Chinh, Nilewski, Christian, Packard, Garrick K, Michels, Theodore, Sprengeler, Paul A, Ernst, Justin T, Reich, Siegfried H, Webster, Kevin R

Get full text